27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Biotech Stocks Hitting 52-week highs on April 24)
- Eleven Biotherapeutics Inc (NASDAQ:EBIO)
Down In The Dumps
(Biotech Stocks Hitting 52-week lows on April 24)
- Acasti Pharma Inc (NASDAQ:ACST) on announcing pricing of a common stock offering
- BioXcel Therapeutics Inc (NASDAQ:BTAI)
- Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
- Paratek Pharmaceuticals Inc (NASDAQ:PRTK)
- Synergy Pharmaceuticals Inc (NASDAQ:SGYP)
Takeda's Relentless Pursuit For Shire
Shire PLC (ADR) (NASDAQ:SHPG) shares rallied 5.64 percent to $173.18 after hours Tuesday, adding to their 2.41 percent advance in the regular session. Japan's Takeda Pharmaceutical Co Ltd (OTC:TKPHF) sweetened its cash and stock offer for the Irish pharma company for the fifth time, raising the offer this time around from $60 billion to $64.3 billion.
Shire's willingness to consider the proposal, contingent on certain conditions being met, suggest it may be finally coming around.
Edward Lifesciences Plunges On Weak Guidance
Edwards Lifesciences Corp (NYSE:EW) shares took a tumble in after hours Tuesday after it reported Q1 adjusted sales of $938 million, up 9.3 percent year-over-year, and adjusted earnings per share of $1.22, up 29.8 percent.
The company raised its 2018 adjusted earnings per share guidance from $4.43-$4.63 to $4.50-$4.70, while issuing downbeat Q2 guidance.
Sangamo Dips On Common Stock Offering
Sangamo Therapeutics Inc (NASDAQ:SGMO) shares were off 6.77 percent at $16.60 after hours Tuesday after the company announced a $200-million common stock offering.
Amgen Shares Trip Despite Beat
Amgen, Inc. (NASDAQ:AMGN) fell by 0.55 percent to $171 in after hours after it reported better-than-expected Q1 results, thanks to strong product sales and a lower tax rate. The company raised the lower-end of its full-year revenue and earnings per share guidance.
More Trouble For Menlo as Japanese Study Halted
Menlo Therapeutics Inc (NASDAQ:MNLO), which saw its stock plummet 77 percent on April 9 on a failed Phase 2 study of its skin condition treatment seriopitant, came under pressure yet again. The stock was down 9.49 percent to $7.25 after its Japanese partner JT Torii decided to halt the recently initiated Phase 2 study of seriopitant in Japan.
On The Radar
The following companies report earnings on Wednesday:
- Integra Lifesciences Holdings Corp (NASDAQ:IART) - Q1 Adj. EPS $0.58 Beats $0.49 Est., Sales $357.1M Beats $349.1M Est.
- The Medicines Company (NASDAQ:MDCO) - Q1 EPS $(0.76) Beats $(0.78) Est., Sales $7.77M Misses $7.99M Est.
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Expectations call for EPS of $(0.18), Sales of $348.57M
Related Links:
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!